TrialThe Lancet. Oncology2022

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.

Luis A Diaz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.